SCHEMBL4034485

SCHEMBL4034485

CC(C)(C)Oc1ccc(-c2c(C#N)c(N)nc(Sc3ccccc3)c2C#N)cc1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.63
NPSR1 Q6W5P4 4/20 0.63
RXFP1 Q9HBX9 2/20 0.63
ADORA1 P30542 11/20 0.52
KDM4E B2RXH2 6/20 0.49
MEN1 O00255 3/20 0.49
ALOX15 P16050 3/20 0.49
KMT2A Q03164 3/20 0.49
HSD17B10 Q99714 3/20 0.49
HTT P42858 2/20 0.49
LMNA P02545 1/20 0.49
MAPK1 P28482 1/20 0.49
ALDH1A1 P00352 4/20 0.47
ADORA2B P29275 1/20 0.46
HPGD P15428 2/20 0.45
USP2 O75604 1/20 0.45
TP53 P04637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
RET P07949 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3333404 0.87 MAPT (0.81) MAPTNPSR1RXFP1ADORA1KDM4E
SCHEMBL245593 0.84 ADORA1 (0.64) MAPTNPSR1RXFP1ADORA1KDM4E
SCHEMBL241556 0.81 MAPT (0.59) MAPTNPSR1RXFP1ADORA1KDM4E
SCHEMBL244863 0.81 ADORA1 (0.61) MAPTNPSR1RXFP1ADORA1KDM4E
SCHEMBL13938147 0.81 ADORA1 (0.62) MAPTNPSR1RXFP1ADORA1KDM4E
SCHEMBL15286658 0.81 ADORA1 (0.64) MAPTNPSR1RXFP1ADORA1KDM4E
SCHEMBL28185531 0.77 KDM4E (0.73) MAPTNPSR1RXFP1ADORA1KDM4E
SCHEMBL6462984 0.77 MAPT (0.59) MAPTNPSR1RXFP1ADORA1KDM4E
SCHEMBL3556602 0.76 ADORA2B (0.68) MAPTNPSR1RXFP1ADORA1KDM4E
SCHEMBL923745 0.76 MAPT (0.52) MAPTNPSR1RXFP1ADORA1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130040992-A1 Substituted 2, 6-Diamino-3, 5-Dicyano-4-Aryl-Pyridines And Their Use As Adenosine-Receptor-Selective Ligands BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-14 US disclosed
US-20130040992-A1 Substituted 2, 6-Diamino-3, 5-Dicyano-4-Aryl-Pyridines And Their Use As Adenosine-Receptor-Selective Ligands BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-14 US disclosed
US-20130040992-A1 Substituted 2, 6-Diamino-3, 5-Dicyano-4-Aryl-Pyridines And Their Use As Adenosine-Receptor-Selective Ligands BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-02-14 US disclosed
US-8242281-B2 Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-08-14 US disclosed
US-8242281-B2 Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-08-14 US disclosed
US-8242281-B2 Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-08-14 US disclosed
EP-1373265-B1 SUBSTITUTED 2,6-DIAMINO-3,5-DICYANO-4-ARYL-PYRIDINES AND THEIR USE AS ADENOSINE RECEPTOR-SELECTIVE LIGANDS BAYER HEALTHCARE AG (DE) 2009-05-06 EP disclosed
US-20070213372-A1 Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands BAYER AKTIENGESELLSCHAFT (DE) 2007-09-13 US disclosed
US-20070213372-A1 Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands BAYER AKTIENGESELLSCHAFT (DE) 2007-09-13 US disclosed
US-20070213372-A1 Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands BAYER AKTIENGESELLSCHAFT (DE) 2007-09-13 US disclosed
US-20040162427-A1 Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligands BAYER AKTIENGESELLSCHAFT (DE) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162427-A1 Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligands ADORA2A, ADORA3, ADORA1 MAPT 4364/4885NPSR1 81/4885RXFP1 353/4885
US-20130040992-A1 Substituted 2, 6-Diamino-3, 5-Dicyano-4-Aryl-Pyridines And Their Use As Adenosine-Receptor-Selective Ligands ADORA3, ADORA1, ADORA2A MAPT 4350/4885NPSR1 264/4885RXFP1 355/4885
US-20070213372-A1 Substituted 2, 6-diamino-3, 5-dicyano-4-arylpyridines and their use as adenosine-receptor-selective ligands ADORA3, ADORA1, ADORA2A MAPT 4461/4885NPSR1 272/4885RXFP1 380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.